<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20240131170750
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20240131170750" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0)</generator>
<language>en</language>
<lastbuilddate>Wed, 31 Jan 2024 22:07:51 +0000</lastbuilddate>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>What Is Your Secret to Health?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38294819/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 31. doi: 10.1001/jamacardio.2023.5344. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38294819/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38294819</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5344>10.1001/jamacardio.2023.5344</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38294819</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Rebecca Ann Levine</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>What Is Your Secret to Health?</dc:title>
<dc:identifier>pmid:38294819</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5344</dc:identifier>
</item>
<item>
<title>Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38294795/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: Implementing routine clinical data, this multicenter cohort study derived and validated the STOP-RVF calculator as a personalized risk assessment tool for the prediction of RVF and RVF-associated all-cause mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 31. doi: 10.1001/jamacardio.2023.5372. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The existing models predicting right ventricular failure (RVF) after durable left ventricular assist device (LVAD) support might be limited, partly due to lack of external validation, marginal predictive power, and absence of intraoperative characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To derive and validate a risk model to predict RVF after LVAD implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a hybrid prospective-retrospective multicenter cohort study conducted from April 2008 to July 2019 of patients with advanced heart failure (HF) requiring continuous-flow LVAD. The derivation cohort included patients enrolled at 5 institutions. The external validation cohort included patients enrolled at a sixth institution within the same period. Study data were analyzed October 2022 to August 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Study participants underwent chronic continuous-flow LVAD support.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary outcome was RVF incidence, defined as the need for RV assist device or intravenous inotropes for greater than 14 days. Bootstrap imputation and adaptive least absolute shrinkage and selection operator variable selection techniques were used to derive a predictive model. An RVF risk calculator (STOP-RVF) was then developed and subsequently externally validated, which can provide personalized quantification of the risk for LVAD candidates. Its predictive accuracy was compared with previously published RVF scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The derivation cohort included 798 patients (mean [SE] age, 56.1 [13.2] years; 668 male [83.7%]). The external validation cohort included 327 patients. RVF developed in 193 of 798 patients (24.2%) in the derivation cohort and 107 of 327 patients (32.7%) in the validation cohort. Preimplant variables associated with postoperative RVF included nonischemic cardiomyopathy, intra-aortic balloon pump, microaxial percutaneous left ventricular assist device/venoarterial extracorporeal membrane oxygenation, LVAD configuration, Interagency Registry for Mechanically Assisted Circulatory Support profiles 1 to 2, right atrial/pulmonary capillary wedge pressure ratio, use of angiotensin-converting enzyme inhibitors, platelet count, and serum sodium, albumin, and creatinine levels. Inclusion of intraoperative characteristics did not improve model performance. The calculator achieved a C statistic of 0.75 (95% CI, 0.71-0.79) in the derivation cohort and 0.73 (95% CI, 0.67-0.80) in the validation cohort. Cumulative survival was higher in patients composing the low-risk group (estimated &lt;20% RVF risk) compared with those in the higher-risk groups. The STOP-RVF risk calculator exhibited a significantly better performance than commonly used risk scores proposed by Kormos et al (C statistic, 0.58; 95% CI, 0.53-0.63) and Drakos et al (C statistic, 0.62; 95% CI, 0.57-0.67).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Implementing routine clinical data, this multicenter cohort study derived and validated the STOP-RVF calculator as a personalized risk assessment tool for the prediction of RVF and RVF-associated all-cause mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38294795/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38294795</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5372>10.1001/jamacardio.2023.5372</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38294795</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Iosif Taleb</dc:creator>
<dc:creator>Christos P Kyriakopoulos</dc:creator>
<dc:creator>Robyn Fong</dc:creator>
<dc:creator>Naila Ijaz</dc:creator>
<dc:creator>Zachary Demertzis</dc:creator>
<dc:creator>Konstantinos Sideris</dc:creator>
<dc:creator>Omar Wever-Pinzon</dc:creator>
<dc:creator>Antigone G Koliopoulou</dc:creator>
<dc:creator>Michael J Bonios</dc:creator>
<dc:creator>Rohan Shad</dc:creator>
<dc:creator>Adithya Peruri</dc:creator>
<dc:creator>Thomas C Hanff</dc:creator>
<dc:creator>Elizabeth Dranow</dc:creator>
<dc:creator>Theodoros V Giannouchos</dc:creator>
<dc:creator>Ethan Krauspe</dc:creator>
<dc:creator>Cyril Zakka</dc:creator>
<dc:creator>Daniel G Tang</dc:creator>
<dc:creator>Hassan W Nemeh</dc:creator>
<dc:creator>Josef Stehlik</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Craig H Selzman</dc:creator>
<dc:creator>Rami Alharethi</dc:creator>
<dc:creator>William T Caine</dc:creator>
<dc:creator>Jennifer A Cowger</dc:creator>
<dc:creator>William Hiesinger</dc:creator>
<dc:creator>Palak Shah</dc:creator>
<dc:creator>Stavros G Drakos</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Machine Learning Multicenter Risk Model to Predict Right Ventricular Failure After Mechanical Circulatory Support: The STOP-RVF Score</dc:title>
<dc:identifier>pmid:38294795</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5372</dc:identifier>
</item>
<item>
<title>Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38294787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>CONCLUSIONS AND RELEVANCE: In this pooled cohort study, the presence of FH variants was associated with a 2-fold higher CHD risk, even when LDL-C was only moderately elevated. The increased CHD risk appeared to be largely explained by the higher cumulative LDL-C exposure in individuals with an FH variant compared to those without. Further research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jan 31. doi: 10.1001/jamacardio.2023.5366. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Familial hypercholesterolemia (FH) is a genetic disorder that often results in severely high low-density lipoprotein cholesterol (LDL-C) and high risk of premature coronary heart disease (CHD). However, the impact of FH variants on CHD risk among individuals with moderately elevated LDL-C is not well quantified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess CHD risk associated with FH variants among individuals with moderately (130-189 mg/dL) and severely (≥190 mg/dL) elevated LDL-C and to quantify excess CHD deaths attributable to FH variants in US adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: A total of 21 426 individuals without preexisting CHD from 6 US cohort studies (Atherosclerosis Risk in Communities study, Coronary Artery Risk Development in Young Adults study, Cardiovascular Health Study, Framingham Heart Study Offspring cohort, Jackson Heart Study, and Multi-Ethnic Study of Atherosclerosis) were included, 63 of whom had an FH variant. Data were collected from 1971 to 2018, and the median (IQR) follow-up was 18 (13-28) years. Data were analyzed from March to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: LDL-C, cumulative past LDL-C, FH variant status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cox proportional hazards models estimated associations between FH variants and incident CHD. The Cardiovascular Disease Policy Model projected excess CHD deaths associated with FH variants in US adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 21 426 individuals without preexisting CHD (mean [SD] age 52.1 [15.5] years; 12 041 [56.2%] female), an FH variant was found in 22 individuals with moderately elevated LDL-C (0.3%) and in 33 individuals with severely elevated LDL-C (2.5%). The adjusted hazard ratios for incident CHD comparing those with and without FH variants were 2.9 (95% CI, 1.4-6.0) and 2.6 (95% CI, 1.4-4.9) among individuals with moderately and severely elevated LDL-C, respectively. The association between FH variants and CHD was slightly attenuated when further adjusting for baseline LDL-C level, whereas the association was no longer statistically significant after adjusting for cumulative past LDL-C exposure. Among US adults 20 years and older with no history of CHD and LDL-C 130 mg/dL or higher, more than 417 000 carry an FH variant and were projected to experience more than 12 000 excess CHD deaths in those with moderately elevated LDL-C and 15 000 in those with severely elevated LDL-C compared with individuals without an FH variant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this pooled cohort study, the presence of FH variants was associated with a 2-fold higher CHD risk, even when LDL-C was only moderately elevated. The increased CHD risk appeared to be largely explained by the higher cumulative LDL-C exposure in individuals with an FH variant compared to those without. Further research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38294787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38294787</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.5366>10.1001/jamacardio.2023.5366</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38294787</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Yiyi Zhang</dc:creator>
<dc:creator>Jacqueline S Dron</dc:creator>
<dc:creator>Brandon K Bellows</dc:creator>
<dc:creator>Amit V Khera</dc:creator>
<dc:creator>Junxiu Liu</dc:creator>
<dc:creator>Pallavi P Balte</dc:creator>
<dc:creator>Elizabeth C Oelsner</dc:creator>
<dc:creator>Sami Samir Amr</dc:creator>
<dc:creator>Matthew S Lebo</dc:creator>
<dc:creator>Anna Nagy</dc:creator>
<dc:creator>Gina M Peloso</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:creator>Jerome I Rotter</dc:creator>
<dc:creator>Cristen Willer</dc:creator>
<dc:creator>Eric Boerwinkle</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Pamela L Lutsey</dc:creator>
<dc:creator>Myriam Fornage</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:creator>Lifang Hou</dc:creator>
<dc:creator>Bruce M Psaty</dc:creator>
<dc:creator>Joshua C Bis</dc:creator>
<dc:creator>James S Floyd</dc:creator>
<dc:creator>Ramachandran S Vasan</dc:creator>
<dc:creator>Nancy L Heard-Costa</dc:creator>
<dc:creator>April P Carson</dc:creator>
<dc:creator>Michael E Hall</dc:creator>
<dc:creator>Stephen S Rich</dc:creator>
<dc:creator>Xiuqing Guo</dc:creator>
<dc:creator>Dhruv S Kazi</dc:creator>
<dc:creator>Sarah D de Ferranti</dc:creator>
<dc:creator>Andrew E Moran</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol</dc:title>
<dc:identifier>pmid:38294787</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.5366</dc:identifier>
</item>
<item>
<title>Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38291599/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>CONCLUSIONS: Systolic BPV is a strong predictor of CV outcome, even in those with controlled SBP. The long-term benefits of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to be primarily mediated by an effect on systolic BPV during the trial period.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 31:ehad814. doi: 10.1093/eurheartj/ehad814. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Visit-to-visit systolic blood pressure variability (BPV) is an important predictor of cardiovascular (CV) outcomes. The long-term effect of a period of blood pressure (BP) control, but with differential BPV, is uncertain. Morbidity and mortality follow-up of UK participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm has been extended for up to 21 years to determine the CV impact of mean systolic blood pressure (SBP) control and BPV during the trial, and amongst those allocated to amlodipine- and atenolol-based treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Eight thousand five hundred and eighty hypertensive participants (4305 assigned to amlodipine ± perindopril-based and 4275 to atenolol ± diuretic-based treatment during the in-trial period (median 5.5 years) were followed for up to 21 years (median 17.4 years), using linked hospital and mortality records. A subgroup of participants (n = 2156) was followed up 6 years after the trial closure with a self-administered questionnaire and a clinic visit. In-trial mean SBP and standard deviation of visit-to-visit SBP as a measure of BPV, were measured using >;100 000 BP measurements. Cox proportional hazard models were used to estimate the risk [hazard ratios (HRs)], associated with (i) mean with SBP and BPV during the in-trial period, for the CV endpoints occurring after the end of the trial and (ii) randomly assigned treatment to events following randomization, for the first occurrence of pre-specified CV outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Using BP data from the in-trial period, in the post-trial period, although mean SBP was a predictor of CV outcomes {HR per 10 mmHg, 1.14 [95% confidence interval (CI) 1.10-1.17], P &lt; .001}, systolic BPV independent of mean SBP was a strong predictor of CV events [HR per 5 mmHg 1.22 (95% CI 1.18-1.26), P &lt; .001] and predicted events even in participants with well-controlled BP. During 21-year follow-up, those on amlodipine-based compared with atenolol-based in-trial treatment had significantly reduced risk of stroke [HR 0.82 (95% CI 0.72-0.93), P = .003], total CV events [HR 0.93 (95% CI 0.88-0.98), P = .008], total coronary events [HR 0.92 (95% CI 0.86-0.99), P = .024], and atrial fibrillation [HR 0.91 (95% CI 0.83-0.99), P = .030], with weaker evidence of a difference in CV mortality [HR 0.91 (95% CI 0.82-1.01), P = .073]. There was no significant difference in the incidence of non-fatal myocardial infarction and fatal coronary heart disease, heart failure, and all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Systolic BPV is a strong predictor of CV outcome, even in those with controlled SBP. The long-term benefits of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to be primarily mediated by an effect on systolic BPV during the trial period.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38291599/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38291599</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad814>10.1093/eurheartj/ehad814</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38291599</guid>
<pubDate>Wed, 31 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Ajay Gupta</dc:creator>
<dc:creator>William N Whiteley</dc:creator>
<dc:creator>Thomas Godec</dc:creator>
<dc:creator>Somayeh Rostamian</dc:creator>
<dc:creator>Cono Ariti</dc:creator>
<dc:creator>Judith Mackay</dc:creator>
<dc:creator>Andrew Whitehouse</dc:creator>
<dc:creator>Leila Janani</dc:creator>
<dc:creator>Neil R Poulter</dc:creator>
<dc:creator>Peter S Sever</dc:creator>
<dc:creator>ASCOT-10 Investigators</dc:creator>
<dc:date>2024-01-31</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial</dc:title>
<dc:identifier>pmid:38291599</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad814</dc:identifier>
</item>
<item>
<title>Ultra-processed foods and cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38291181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jan 30. doi: 10.1038/s41569-024-00990-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38291181/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38291181</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00990-7>10.1038/s41569-024-00990-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38291181</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Fernanda Rauber</dc:creator>
<dc:creator>Renata Bertazzi Levy</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Ultra-processed foods and cardiovascular disease</dc:title>
<dc:identifier>pmid:38291181</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00990-7</dc:identifier>
</item>
<item>
<title>A 25-year odyssey of genomic technology advances and structural variant discovery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38290514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>This perspective focuses on advances in genome technology over the last 25 years and their impact on germline variant discovery within the field of human genetics. The field has witnessed tremendous technological advances from microarrays to short-read sequencing and now long-read sequencing. Each technology has provided genome-wide access to different classes of human genetic variation. We are now on the verge of comprehensive variant detection of all forms of variation for the first time with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jan 23:S0092-8674(24)00004-7. doi: 10.1016/j.cell.2024.01.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This perspective focuses on advances in genome technology over the last 25 years and their impact on germline variant discovery within the field of human genetics. The field has witnessed tremendous technological advances from microarrays to short-read sequencing and now long-read sequencing. Each technology has provided genome-wide access to different classes of human genetic variation. We are now on the verge of comprehensive variant detection of all forms of variation for the first time with a single assay. We predict that this transition will further transform our understanding of human health and biology and, more importantly, provide novel insights into the dynamic mutational processes shaping our genomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38290514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38290514</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.01.002>10.1016/j.cell.2024.01.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38290514</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>David Porubsky</dc:creator>
<dc:creator>Evan E Eichler</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A 25-year odyssey of genomic technology advances and structural variant discovery</dc:title>
<dc:identifier>pmid:38290514</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.01.002</dc:identifier>
</item>
<item>
<title>Colchicine to prevent sympathetic denervation after acute myocardial infarction: the COLD-MI trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289979/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae042. doi: 10.1093/eurheartj/ehae042. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289979/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289979</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae042>10.1093/eurheartj/ehae042</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289979</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Fabien Huet</dc:creator>
<dc:creator>Denis Mariano-Goulart</dc:creator>
<dc:creator>Sylvain Aguilhon</dc:creator>
<dc:creator>Quentin Delbaere</dc:creator>
<dc:creator>Alain Lacampagne</dc:creator>
<dc:creator>Jérémy Fauconnier</dc:creator>
<dc:creator>Florence Leclercq</dc:creator>
<dc:creator>Jean-Christophe Macia</dc:creator>
<dc:creator>Mariama Akodad</dc:creator>
<dc:creator>Nidal Jammoul</dc:creator>
<dc:creator>Fabrice Prunier</dc:creator>
<dc:creator>Nathan Mewton</dc:creator>
<dc:creator>Denis Angoulvant</dc:creator>
<dc:creator>Catherine Lozza</dc:creator>
<dc:creator>Sonia Soltani</dc:creator>
<dc:creator>Annabelle Rodier</dc:creator>
<dc:creator>Sylvie Grandemange</dc:creator>
<dc:creator>Anne-Marie Dupuy</dc:creator>
<dc:creator>Jean-Paul Cristol</dc:creator>
<dc:creator>Mailis Amico</dc:creator>
<dc:creator>Nicolas Nagot</dc:creator>
<dc:creator>François Roubille</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Colchicine to prevent sympathetic denervation after acute myocardial infarction: the COLD-MI trial</dc:title>
<dc:identifier>pmid:38289979</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae042</dc:identifier>
</item>
<item>
<title>Utility of vector flow mapping and [18F]fluorodeoxyglucose-positron emission tomography/computed tomography to assess left ventricular workload in obstructive hypertrophic cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae005. doi: 10.1093/eurheartj/ehae005. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289896</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae005>10.1093/eurheartj/ehae005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289896</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Nobuhiro Tahara</dc:creator>
<dc:creator>Yoshihiro Fukumoto</dc:creator>
<dc:creator>Eiki Tayama</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Utility of vector flow mapping and [18F]fluorodeoxyglucose-positron emission tomography/computed tomography to assess left ventricular workload in obstructive hypertrophic cardiomyopathy</dc:title>
<dc:identifier>pmid:38289896</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae005</dc:identifier>
</item>
<item>
<title>Electrical storm treatment by percutaneous stellate ganglion block: the STAR study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>CONCLUSIONS: The findings of this large, prospective, multicentre study provide evidence in favour of the effectiveness and safety of PSGB for the treatment of refractory ES.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae021. doi: 10.1093/eurheartj/ehae021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: An electrical storm (ES) is a clinical emergency with a paucity of established treatment options. Despite initial encouraging reports about the safety and effectiveness of percutaneous stellate ganglion block (PSGB), many questions remained unsettled and evidence from a prospective multicentre study was still lacking. For these purposes, the STAR study was designed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a multicentre observational study enrolling patients suffering from an ES refractory to standard treatment from 1 July 2017 to 30 June 2023. The primary outcome was the reduction of treated arrhythmic events by at least 50% comparing the 12 h following PSGB with the 12 h before the procedure. STAR operators were specifically trained to both the anterior anatomical and the lateral ultrasound-guided approach.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 131 patients from 19 centres were enrolled and underwent 184 PSGBs. Patients were mainly male (83.2%) with a median age of 68 (63.8-69.2) years and a depressed left ventricular ejection fraction (25.0 ± 12.3%). The primary outcome was reached in 92% of patients, and the median reduction of arrhythmic episodes between 12 h before and after PSGB was 100% (interquartile range -100% to -92.3%). Arrhythmic episodes requiring treatment were significantly reduced comparing 12 h before the first PSGB with 12 h after the last procedure [six (3-15.8) vs. 0 (0-1), P &lt; .0001] and comparing 1 h before with 1 h after each procedure [2 (0-6) vs. 0 (0-0), P &lt; .001]. One major complication occurred (0.5%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The findings of this large, prospective, multicentre study provide evidence in favour of the effectiveness and safety of PSGB for the treatment of refractory ES.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289867</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae021>10.1093/eurheartj/ehae021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289867</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Simone Savastano</dc:creator>
<dc:creator>Enrico Baldi</dc:creator>
<dc:creator>Sara Compagnoni</dc:creator>
<dc:creator>Roberto Rordorf</dc:creator>
<dc:creator>Antonio Sanzo</dc:creator>
<dc:creator>Francesca Romana Gentile</dc:creator>
<dc:creator>Veronica Dusi</dc:creator>
<dc:creator>Simone Frea</dc:creator>
<dc:creator>Carol Gravinese</dc:creator>
<dc:creator>Filippo Maria Cauti</dc:creator>
<dc:creator>Gianmarco Iannopollo</dc:creator>
<dc:creator>Francesco De Sensi</dc:creator>
<dc:creator>Edoardo Gandolfi</dc:creator>
<dc:creator>Laura Frigerio</dc:creator>
<dc:creator>Pasquale Crea</dc:creator>
<dc:creator>Domenico Zagari</dc:creator>
<dc:creator>Matteo Casula</dc:creator>
<dc:creator>Giuseppe Sangiorgi</dc:creator>
<dc:creator>Simone Persampieri</dc:creator>
<dc:creator>Gabriele Dell'Era</dc:creator>
<dc:creator>Giuseppe Patti</dc:creator>
<dc:creator>Claudia Colombo</dc:creator>
<dc:creator>Giacomo Mugnai</dc:creator>
<dc:creator>Francesco Notaristefano</dc:creator>
<dc:creator>Alberto Barengo</dc:creator>
<dc:creator>Roberta Falcetti</dc:creator>
<dc:creator>Giovanni Battista Perego</dc:creator>
<dc:creator>Giuseppe D'Angelo</dc:creator>
<dc:creator>Nikita Tanese</dc:creator>
<dc:creator>Alessia Currao</dc:creator>
<dc:creator>Vito Sgromo</dc:creator>
<dc:creator>Gaetano Maria De Ferrari</dc:creator>
<dc:creator>STAR study group</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Electrical storm treatment by percutaneous stellate ganglion block: the STAR study</dc:title>
<dc:identifier>pmid:38289867</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae021</dc:identifier>
</item>
<item>
<title>Plasma proteins can tell your biological organs' age (including the heart)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae038. doi: 10.1093/eurheartj/ehae038. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289864</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae038>10.1093/eurheartj/ehae038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289864</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Plasma proteins can tell your biological organs' age (including the heart)</dc:title>
<dc:identifier>pmid:38289864</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae038</dc:identifier>
</item>
<item>
<title>On the importance of birth weight in relation to disease risk in later life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289862/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehad785. doi: 10.1093/eurheartj/ehad785. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289862/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289862</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad785>10.1093/eurheartj/ehad785</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289862</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>Harold Snieder</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>On the importance of birth weight in relation to disease risk in later life</dc:title>
<dc:identifier>pmid:38289862</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad785</dc:identifier>
</item>
<item>
<title>To test or not to test for ischaemia routinely after percutaneous coronary intervention in diabetic patients: is the jury still out?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehad877. doi: 10.1093/eurheartj/ehad877. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289834</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad877>10.1093/eurheartj/ehad877</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289834</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Roxy Senior</dc:creator>
<dc:creator>Rajdeep S Khattar</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>To test or not to test for ischaemia routinely after percutaneous coronary intervention in diabetic patients: is the jury still out?</dc:title>
<dc:identifier>pmid:38289834</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad877</dc:identifier>
</item>
<item>
<title>Transatlantic differences in the use of implantable cardioverter defibrillators in arrhythmogenic right ventricular cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289329/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae022. doi: 10.1093/eurheartj/ehae022. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289329/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289329</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae022>10.1093/eurheartj/ehae022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289329</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Perry Mark Elliott</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transatlantic differences in the use of implantable cardioverter defibrillators in arrhythmogenic right ventricular cardiomyopathy</dc:title>
<dc:identifier>pmid:38289329</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae022</dc:identifier>
</item>
<item>
<title>The 2023 ESC guidelines for the management of cardiomyopathies: the 10 commandments</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289320/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehad858. doi: 10.1093/eurheartj/ehad858. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289320/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289320</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad858>10.1093/eurheartj/ehad858</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289320</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Juan Pablo Kaski</dc:creator>
<dc:creator>Elena Arbelo</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The 2023 ESC guidelines for the management of cardiomyopathies: the 10 commandments</dc:title>
<dc:identifier>pmid:38289320</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad858</dc:identifier>
</item>
<item>
<title>A translational approach towards understanding brain waste clearance in cerebral amyloid angiopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289319/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae011. doi: 10.1093/eurheartj/ehae011. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289319</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae011>10.1093/eurheartj/ehae011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289319</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Susanne J van Veluw</dc:creator>
<dc:creator>Helene Benveniste</dc:creator>
<dc:creator>Matthias J P van Osch</dc:creator>
<dc:creator>Leducq Foundation Transatlantic Network of Excellence on Brain Clearance</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A translational approach towards understanding brain waste clearance in cerebral amyloid angiopathy</dc:title>
<dc:identifier>pmid:38289319</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae011</dc:identifier>
</item>
<item>
<title>Mitochondria and the heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38289316/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 30:ehae031. doi: 10.1093/eurheartj/ehae031. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38289316/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38289316</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae031>10.1093/eurheartj/ehae031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38289316</guid>
<pubDate>Tue, 30 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Felippe Henrique Zuccolotto Dos Reis</dc:creator>
<dc:date>2024-01-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Mitochondria and the heart</dc:title>
<dc:identifier>pmid:38289316</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae031</dc:identifier>
</item>
<item>
<title>Deceased donor organ retrieval: impact on cardiovascular research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38285900/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jan 29:ehae033. doi: 10.1093/eurheartj/ehae033. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38285900/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38285900</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae033>10.1093/eurheartj/ehae033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38285900</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Patrícia Afonso Mendes</dc:creator>
<dc:creator>Cristiane Pais Macedo</dc:creator>
<dc:creator>Sónia Moreira</dc:creator>
<dc:creator>Rogério Ferreira</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deceased donor organ retrieval: impact on cardiovascular research</dc:title>
<dc:identifier>pmid:38285900</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae033</dc:identifier>
</item>
<item>
<title>Palpitations and Recurrent Syncope in a Young Woman</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38285741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 30;149(5):402-405. doi: 10.1161/CIRCULATIONAHA.123.067865. Epub 2024 Jan 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38285741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38285741</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067865>10.1161/CIRCULATIONAHA.123.067865</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38285741</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Sun Yong Lee</dc:creator>
<dc:creator>Byron K Lee</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Palpitations and Recurrent Syncope in a Young Woman</dc:title>
<dc:identifier>pmid:38285741</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067865</dc:identifier>
</item>
<item>
<title>The Future of Pediatric and Adult Heart Transplantation: Perspective From the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38285740/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 30;149(5):339-341. doi: 10.1161/CIRCULATIONAHA.123.065450. Epub 2024 Jan 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38285740/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38285740</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065450>10.1161/CIRCULATIONAHA.123.065450</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38285740</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Emile Bacha</dc:creator>
<dc:creator>Maryjane Farr</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Future of Pediatric and Adult Heart Transplantation: Perspective From the United States</dc:title>
<dc:identifier>pmid:38285740</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065450</dc:identifier>
</item>
<item>
<title>LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38285739/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 30;149(5):363-366. doi: 10.1161/CIRCULATIONAHA.123.067241. Epub 2024 Jan 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38285739/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38285739</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067241>10.1161/CIRCULATIONAHA.123.067241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38285739</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Raul D Santos</dc:creator>
<dc:creator>Marina Cuchel</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes</dc:title>
<dc:identifier>pmid:38285739</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067241</dc:identifier>
</item>
<item>
<title>Trajectories of Sleep Over Midlife and Incident Cardiovascular Disease Events in the Study of Women's Health Across the Nation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38284249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240131170750&amp;v=2.18.0
      <description>CONCLUSIONS: Insomnia symptoms, when persistent over midlife or occurring with short sleep, are associated with higher CVD risk among women.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jan 29. doi: 10.1161/CIRCULATIONAHA.123.066491. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Up to 50% of women report sleep problems in midlife, and cardiovascular disease (CVD) is the leading cause of death in women. How chronic poor sleep exposure over decades of midlife is related to CVD risk in women is poorly understood. We tested whether trajectories of insomnia symptoms or sleep duration over midlife were related to subsequent CVD events among SWAN (Study of Women's Health Across the Nation) participants, whose sleep was assessed up to 16 times over 22 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: At baseline, SWAN participants (n=2964) were 42 to 52 years of age, premenopausal or early perimenopausal, not using hormone therapy, and free of CVD. They completed up to 16 visits, including questionnaires assessing insomnia symptoms (trouble falling asleep, waking up several times a night, or waking earlier than planned ≥3 times/week classified as insomnia), typical daily sleep duration, vasomotor symptoms, and depressive symptoms; anthropometric measurements; phlebotomy; and CVD event ascertainment (ie, fatal or nonfatal myocardial infarction, stroke, heart failure, revascularization). Sleep trajectories (ie, insomnia, sleep duration) were determined by means of group-based trajectory modeling. Sleep trajectories were tested in relation to CVD in Cox proportional hazards models (multivariable models: site, age, race and ethnicity, education, CVD risk factors averaged over visits; additional covariates: vasomotor symptoms, snoring, depression).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Four trajectories of insomnia symptoms emerged: low insomnia symptoms (n=1142 [39% of women]), moderate insomnia symptoms decreasing over time (n=564 [19%]), low insomnia symptoms increasing over time (n=590 [20%]), and high insomnia symptoms that persisted (n=668 [23%]). Women with persistently high insomnia symptoms had higher CVD risk (hazard ratio, 1.71 [95% CI, 1.19, 2.46], <i>P</i>=0.004, versus low insomnia; multivariable). Three trajectories of sleep duration emerged: persistently short (~5 hours: n=363 [15%]), moderate (~6 hours: n=1394 [55%]), and moderate to long (~8 hours: n=760 [30%]). Women with persistent short sleep had marginally higher CVD risk (hazard ratio, 1.51 [95% CI, 0.98, 2.33], <i>P</i>=0.06, versus moderate; multivariable). Women who had both persistent high insomnia and short sleep had significantly elevated CVD risk (hazard ratio, 1.75 [95% CI, 1.03, 2.98], <i>P</i>=0.04, versus low insomnia and moderate or moderate to long sleep duration; multivariable). Relations of insomnia to CVD persisted when adjusting for vasomotor symptoms, snoring, or depression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Insomnia symptoms, when persistent over midlife or occurring with short sleep, are associated with higher CVD risk among women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38284249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240131170750&v=2.18.0">38284249</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066491>10.1161/CIRCULATIONAHA.123.066491</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38284249</guid>
<pubDate>Mon, 29 Jan 2024 06:00:00 -0500</pubDate>
<dc:creator>Rebecca C Thurston</dc:creator>
<dc:creator>Yuefang Chang</dc:creator>
<dc:creator>Christopher E Kline</dc:creator>
<dc:creator>Leslie M Swanson</dc:creator>
<dc:creator>Samar R El Khoudary</dc:creator>
<dc:creator>Elizabeth A Jackson</dc:creator>
<dc:creator>Carol A Derby</dc:creator>
<dc:date>2024-01-29</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Trajectories of Sleep Over Midlife and Incident Cardiovascular Disease Events in the Study of Women's Health Across the Nation</dc:title>
<dc:identifier>pmid:38284249</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066491</dc:identifier>
</item>





























</channel>
</rss>